MedPath

Fog Pharmaceuticals, Inc.

Fog Pharmaceuticals, Inc. logo
🇺🇸United States
Ownership
Holding
Established
2015-01-01
Employees
101
Market Cap
-
Website
http://www.fogpharma.com

Clinical Trials

1

Active:0
Completed:0

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Phase 1
Recruiting
Conditions
Cancer
Colorectal Cancer
Solid Tumor
Locally Advanced Solid Tumor
Metastatic Cancer
WNT Pathway
β-catenin
Beta-catenin
Adenomatous Polyposis Coli
APC
Interventions
First Posted Date
2023-06-26
Last Posted Date
2025-07-14
Lead Sponsor
Parabilis Medicines, Inc.
Target Recruit Count
480
Registration Number
NCT05919264
Locations
🇺🇸

Stanford Cancer Institute, Stanford University, Palo Alto, California, United States

🇺🇸

University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

🇺🇸

Honor Health, Scottsdale, Arizona, United States

and more 8 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.